Photodynamic Therapy Using Topical Methyl Aminolevulinate vs Surgery for Nodular Basal Cell Carcinoma: Results of a Multicenter Randomized Prospective Trial

Archives of Dermatology

Volumn 140, Issue 1, 2004, Pages 17-23

  Rhodes, Lesley E ^a,j   De Rie, Menno ^b   Enström, Ylva ^c   Groves, Richard ^d   Morken, Tore ^e   Goulden, Victoria ^f   Wong, Gavin A E ^a   Grob, Jean Jacques ^g   Varma, Sandeep ^h   Wolf, Peter ⁱ  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Norra Älvsborg Hospital   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f LEEDS GENERAL INFIRMARY   (United Kingdom)

^g HÔPITAL SAINTE MARGUERITE   (France)

^h UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

ⁱ UNIVERSITY OF GRAZ   (Austria)

^j UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTHETIC SURGERY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; AMINOLEVULINIC ACID; CARCINOMA, BASAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; OINTMENTS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 9144262975     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.1.17     Document Type: Article

References (23)

1. Slaper H, Velders GJM, Daniel JS, de Gruijl FR, van der Leun JC. Estimates of ozone depletion and skin cancer incidence to examine the Vienna Convention achievements. Nature. 1996;384:256-258.
2. Scott J, Fears TR. Incidence of Non-melanoma Skin Cancer in the United States. Washington, DC: National Institutes of Health; 1981. NIH publication 82-2433.
3. Green A, Battistutta D, Hart V, Leslie D, Weedon D, for the Nambour Study Group. Skin cancer in a subtropical Australian population: incidence and lack of association with occupation. Am J Epidemiol. 1996;144:1034-1040.
4. Marks R. The epidemiology of non-melanoma skin cancer: who, why and what can we do about it. J Dermatol. 1995;22:853-857.
5. Thissen MRTM, Neumann MHA, Schouten LJ. A systematic review of treatment modalities for primary basal cell carcinomas. Arch Dermatol. 1999;135:1177-1183.
6. Telfer NR, Colver GB, Bowers PW. Guidelines for the management of basal cell carcinoma. Br J Dermatol. 1999;141:415-423.
7. Hsi RA, Rosenthal DI, Glatstein E. Photodynamic therapy in the treatment of cancer. Drugs. 1999;57:725-734.
8. Kennedy JC, Pottier RH, Ross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and clinical experience. J Photochem Photobiol B. 1990;6:143-148.
9. Morton CA, Brown SB, Collins S, et al. Guidelines for topical photodynamic therapy. Br J Dermatol. 2002;146:552-567.
10. Peng Q, Warloe T, Berg K, et al. 5-ALA based photodynamic therapy. Cancer. 1997;79:2282-2308.
11. Haller JC, Cairnduff F, Slack G, et al. Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. Br J Dermatol. 2000;143:1270-1274.
12. Peng Q, Moan J, Warloe T, et al. Build-up of esterified aminolevulinic-derivative-induced porphyrin fluorescence in normal skin. J Photochem Photobiol B. 1996; 34:95-96.
13. Kloek J, Beijersbergen van Henegouwen MJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem Photobiol. 1996;64:994-1000.
14. Fritsch C, Homey B, Stahl W, Lehmann P, Ruzicka T, Sies H. Preferential relative porphyrin enrichment in solar keratoses upon topical application of 5-aminolevulinic acid methylester. Photochem Photobiol. 1998;68:218-221.
15. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol. 2001;145:467-471.
16. National Cancer Institute. National Cancer Institute Common Toxicity Criteria. Version 2.0. Bethesda, Md: National Cancer Institute; 1999.
17. Soler A, Warloe T, Tausjø J, Berner A. Photodynamic therapy by topical aminolevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one-year follow-up study. Acta Derm Venereol. 1999;79:204-206.
18. Rowe DE, Carroll RJ, Day CL. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma. J Dermatol Surg Oncol. 1989;15:315-328.
19. Silverman MK, Kopf AW, Bart RS, Grin CM, Levenstein MS. Recurrence rates of treated basal cell carcinomas. J Dermatol Surg Dncol. 1991;17:713-718.
20. Wang I, Bendsoe N, Klinteberg C, et al. Photodynamic therapy versus cryosurgery of basal cell carcinomas. Br J Dermatol. 2001;144:832-840.
21. Szeimies RM, Karrer S, Sauerwald A, Landthaler M. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study. Dermatology. 1996;192:246-251.
22. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid: a pilot dose-ranging study. Arch Dermatol. 1997;133:727-732.
23. Fink-Puches R, Hofer A, Smolle J, Kerl H, Wolf P. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B. 1997;41:145-151.